Enhanced bioavailability and hepatoprotectivity of optimized ursolic acid-phospholipid complex

被引:38
作者
Biswas, Sayan [1 ]
Mukherjee, Pulok K. [1 ]
Harwansh, Ranjit K. [1 ]
Bannerjee, Subhadip [1 ]
Bhattacharjee, Pritorthi [1 ]
机构
[1] Jadavpur Univ, Dept Pharmaceut Technol, Sch Nat Prod Studies, Raja Sc Mullick Rd, Kolkata 700032, India
关键词
Ursolic acid; phospholipid complex; bioavailability; hepatoprotective activity; pharmacokinetics; histopathology; OLEANOLIC ACID; DRUG-DELIVERY; IN-VIVO; ORAL BIOAVAILABILITY; LIVER-DAMAGE; DISSOLUTION; PROFILE; CELLS; VITRO; ASSAY;
D O I
10.1080/03639045.2019.1583755
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Objective: To prepare and characterize an optimized phospholipid complex of Ursolic acid (UA) to overcome the poor pharmacokinetic properties and to investigate the impact of the complex on hepatoprotective activity and bioavailability in animal model.Significance: UA is a potential phytoconstituent obtained from several plant sources, which has been explored for its diverse pharmacological activities including hepatoprotection. Its major limitation is poor absorption, rapid elimination, and hence low bioavailability after administration.Methods: Response surface methodology was adopted to formulate an optimized (UA) complex. The complex was characterized by differential thermal analysis (DTA), Fourier transform-Infrared Spectroscopy, Powder X ray Diffraction, molecular docking, etc. The physico-chemical profile (solubility, oil/water partition coefficient) and in vitro dissolution profile was estimated. The formulation was then used to study hepatoprotective activity and bioavailability in animal models.Results: Results showed that the phospholipid complex of UA has enhanced the hepatoprotective potential as compared to pure UA at the same dose level. The complex restored the levels of serum hepatic marker enzymes with respect to untreated group and increased the relative bioavailability of UA in rat plasma by 8.49-fold in comparison with pure compound at the same dose level. It enhanced the elimination half-life (t(1/2 el)) from 0.69 1.76 to 8.28 1.98 h.Conclusion: Complexation of UA with phospholipid markedly enhanced the hepatoprotective potential of UA by improving its bioavailability and pharmacokinetic parameters.Novelty statementThe present article deals with rational optimization of the formulation parameters for phospholipid complex of ursolic acid by Response Surface Methodology analysis, characterizing the formulation by in silico approach apart from conventional instrumental techniques, and evaluating the in vitro dissolution, pharmacokinetics, and hepatoprotective activity of the complex in animals.Novelty statementThe present article deals with rational optimization of the formulation parameters for phospholipid complex of ursolic acid by Response Surface Methodology analysis, characterizing the formulation by in silico approach apart from conventional instrumental techniques, and evaluating the in vitro dissolution, pharmacokinetics, and hepatoprotective activity of the complex in animals.
引用
收藏
页码:946 / 958
页数:13
相关论文
共 50 条
[31]   A microemulsion of puerarin-phospholipid complex for improving bioavailability: preparation, in vitro and in vivo evaluations [J].
Wu, Jun-Yong ;
Li, Yong-Jiang ;
Han, Meng ;
Hu, Xiong-Bin ;
Yang, Le ;
Wang, Jie-Min ;
Xiang, Da-Xiong .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2018, 44 (08) :1336-1341
[32]   Bioavailability enhancement of formononetin by incorporation of natural bioenhancer in phospholipid complex [J].
Agarwal, Arun ;
Dadge, Shailesh ;
Garg, Richa ;
Sharma, Rakesh Kumar ;
Chauhan, Divya ;
Katekar, Roshan ;
Rathaur, Shivam ;
Mitra, Kalyan ;
Gayen, Jiaur R. .
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2024, 29 (10) :1148-1161
[33]   Cabozantinib-phospholipid complex for enhanced solubility, bioavailability, and reduced toxicity in liver cancer [J].
Patil, Jayesh ;
Bhattacharya, Sankha ;
Saoji, Suprit D. ;
Dande, Payal .
THERAPEUTIC DELIVERY, 2025, 16 (01) :25-41
[34]   Self nanoemulsifying drug delivery system of stabilized ellagic acid-phospholipid complex with improved dissolution and permeability [J].
Avachat, Amelia M. ;
Patel, Vijay G. .
SAUDI PHARMACEUTICAL JOURNAL, 2015, 23 (03) :276-289
[35]   A phospholipid complex to improve the oral bioavailability of flavonoids [J].
Wang, Huizhen ;
Cui, Yuqing ;
Fu, Qingxue ;
Deng, Bing ;
Li, Guowen ;
Yang, Jun ;
Wu, Tao ;
Xie, Yan .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2015, 41 (10) :1693-1703
[36]   Preparation and Body Distribution of Freeze-Dried Powder of Ursolic Acid Phospholipid Nanoparticles [J].
Zhou, Xiao Ju ;
Hu, Xian Ming ;
Yi, Yi Mu ;
Wan, Jing .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2009, 35 (03) :305-310
[37]   Ursolic Acid Nanocrystals for Dissolution Rate and Bioavailability Enhancement: Influence of Different Particle Size [J].
Pi, Jiaxin ;
Liu, Zhidong ;
Wang, Hao ;
Gu, Xing ;
Wang, Shuya ;
Zhang, Bing ;
Luan, Hansen ;
Zhu, Zhuangzhi .
CURRENT DRUG DELIVERY, 2016, 13 (08) :1358-1366
[38]   Effect and mechanism of edible oil co-digestion on the bioaccessibility and bioavailability of ursolic acid [J].
Liu, Yugang ;
Xia, Huiping ;
Guo, Shiyin ;
Li, Peiwang ;
Qin, Si ;
Shi, Meng ;
Zeng, Chaoxi .
FOOD CHEMISTRY, 2023, 423
[39]   Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol [J].
Singh, Bhupinder ;
Singh, Ramandeep ;
Bandyopadhyay, Shantanu ;
Kapil, Rishi ;
Garg, Babita .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2013, 101 :465-474
[40]   Chlorogenic acid-optimized nanophytovesicles: a novel approach for enhanced permeability and oral bioavailability [J].
Trivedi, Hemangi R. ;
Puranik, Prashant K. .
FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 9 (01)